INTRODUCTION
The demand for antisense oligonucleotides (AONs) is increasing due to their use as a tool for gene validation in drug discovery and their potential as a new class of drugs for the treatment of diseases such as cancer, inflammation and viral diseases.
1) The action mechanisms of AONs involve translation arrest, mRNA degradation mediated by RNase H and splicing arrest as shown in Fig. 1 . Phosphorothioate oligodeoxynucleotides (PS ODN, b in Fig. 2 ), which are used as popular antisense molecules, have favorable properties such as nuclease resistance, and are able to be recognized by RNase H. 1, 2) One PS ODN is in the market and others are under clinical testing. [1] [2] [3] However, they have drawbacks in their use, such as low affinity to RNA (DT m ϭϪ0.5-1°C per modification) and nonsequence-specific protein binding, which would be the cause of significant side effects, such as inhibition of the blood clotting cascade, activation of the complement cascade and severe hypotension in vivo. 1) Many researchers have focused on the development of other types of modified oligonucleotides as next-generation AONs.
1,4) 2Ј-O-Alkyl modifications are known to be of value in enhancing the binding affinity to target RNA and nuclease resistance. 5) In particular, a 2Ј-O-(2-methoxy)ethyl modification (2Ј-MOE) showed high RNA affinity (DT m ϭϩ2°C per modification) with high nuclease stability (c in Fig. 2 ). Some oligonucleotide gapmers with four or five 2Ј-MOE residues at both the 3Ј and 5Ј ends, which target TNF-a mRNA to inhibit inflammation and PTP1B mRNA to improve diabetes are in the clinical stages. 3, 6) Morpholino oligonucleotides are capable of hybridizing to mRNA with thermal stability (DT m ϭnot more than 1°C per modification) due to the elimination of anionic repulsion between the phosphodiesters (d in Fig. 2 ). hybridize to mRNA with increasing thermal stability (DT m ϭ ϩ2.2-2.6°C per modification). 8) Oligonucleotides, such as GRN163, comprising NPS residues have been reported as telomerase inhibitors, which could act as novel antitumor agents. 9) Imanishi's group and Wengel's group have independently reported the synthesis of novel 2Ј-O,4Ј-C-methylene nucleosides whose sugar puckering is fixed in the N-conformation as in RNA (f in Fig. 2 ), and that oligonucleotides containing these bridged nucleosides (2Ј,4Ј-BNA/LNA) showed an unprecedented level of affinity toward their complementary RNA (DT m ϭϩ3-8°C per modification). [10] [11] [12] Recently, we have reported the synthesis of novel 2Ј-O,4Ј-C-ethylene thymidine, which has a less-strained six-membered ring than the five-membered ring of 2Ј-O,4Ј-C-methylene thymidine (g in Fig. 2 ).
13) The corresponding oligonucleotides with 2Ј-O,4Ј-C-ethylene nucleosides retain a binding affinity to ssDNA and ssRNA as high as 2Ј,4Ј-BNA/LNA and show excellent triplex formation with dsDNA. [13] [14] [15] They also exhibit much higher nuclease-resistance than 2Ј,4Ј-BNA/LNA. [13] [14] [15] Here, we review the properties of 2Ј-O,4Ј-C-ethylenebridged nucleic acids (ENA) having 2Ј-O,4Ј-C-ethylene nucleosides and the application of their oligonucleotides for use as antisense and antigene oligonucleotides.
CONFORMATIONAL PROPERTIES OF 2Ј-O,4Ј-C-ETHYLENE NUCLEOSIDES
2Ј-O,4Ј-C-Ethylene nucleosides and their corresponding phosphoramidites containing all possible natural bases have been synthesized. 13, 14) The conformational analysis of 2Ј-O,4Ј-C-ethylene nucleosides by 1 H-NMR has shown that in all 2Ј-O,4Ј-C-ethylene nucleosides, the coupling constant (J H1Ј-H2Ј ) was 0 Hz, which was identical to that of 2Ј-O,4Ј-Cmethylene nucleosides. 14) This means that the furanose puckering of 2Ј-O,4Ј-C-ethylene nucleosides are all fixed in the C3Ј-endo conformation (Fig. 2, g ). Similar results have been obtained by X-ray crystal structure analysis of the 2Ј-O,4Ј-Cethylene nucleosides, which show typical C3Ј-endo conformations. 14, 15) The difference between 2Ј-O,4Ј-C-ethylene nucleosides and 2Ј-O,4Ј-C-methylene nucleosides appear clearly in the d torsion angle of C5Ј-C4Ј-C3Ј-O3Ј (Fig. 2, f,  g ), which is one of the defining angles of the ribose conformation. 16) It has been reported that the mean d angles of 2Ј-O,4Ј-C-ethylene nucleosides (Fig. 2, g ) and 2Ј-O,4Ј-C-methylene nucleosides (Fig. 2, f) are 77°and 66°, respectively. 15) From the viewpoint of oligonucleotide structure, this conformation and this difference of the d angle in each nucleoside unit influences the antisense and triplex formation of oligonucleotides with complementary RNA and dsDNA, respectively, as explained below.
NUCLEASE RESISTANCE OF ENA OLIGONU-CLEOTIDES
It is thought that stable oligonucleotides in plasma might be used in antisense and antigene therapeutics.
1) Oligonucleotides modified with an ENA residue at the second position from the 3Ј end have shown greater stability against exoand endonucleases than those modified with a 2Ј,4Ј-BNA/LNA residue. 13, 14) The stability of an oligonucleotide modified with an ENA residue is identical to that of an oligonucleotide with a PS Rp diastereomer. An oligonucleotide containing two ENA residues at the 3Ј end is more stable than an oligonucleotide with a PS Sp diastereomer, which is known to be a stable isomer. Oligonucleotides composed of contiguous ENA residues without PS modification show greater nuclease stability than PS ODN. Furthermore, the stability of ENA oligonucleotides in rat plasma has been reported. 17) ENA gapmers with a PS ODN center still remain even after 24 h. They are more stable than PS ODN and 2Ј,4Ј-BNA/LNA oligonucleotides, of which half are degraded in 4 h in rat plasma.
DUPLEX FORMATION OF ENA OLIGONUCLEO-TIDES WITH RNA AS ANTISENSE MOLECULES
It has been reported that the duplexes of an oligonucleotide containing ENA residues and its complementary RNA have a higher UV melting temperature (T m ) than a natural DNA/DNA and DNA/RNA duplex by ϩ3.5-5°C per residue modification, which is also the case for duplexes containing 2Ј,4Ј-BNA/LNA residues. 13, 14) Based on the CD spectra, although DNA/DNA duplexes usually show a B conformation, incorporation of some ENA residues into DNA/DNA duplexes changed the conformation from B to an A-like conformation. 14) In the case of complementary RNA, both the CD spectrum of a duplex containing 2Ј,4Ј-BNA/LNA residues and that containing ENA residues indicated an A-like conformation. 14) Although a duplex of an ENA oligonucleotide with the complementary RNA is not a substrate for RNase H, a duplex of a DNA-ENA-DNA gapmer-designed oligonucleotide with the complementary RNA is cleaved by RNase H. This cleavage rate is much faster than that of a natural DNA/RNA duplex, possibly due to a higher binding activity of the oligonucleotide containing ENA residues. 17) 
TRIPLEX FORMATION OF ENA OLIGONUCLEO-TIDES WITH dsDNA AS ANTIGENE MOLECULES
Antigene molecules that inhibit gene expression by binding to dsDNA in a sequence-specific manner and block tran- 454 Vol. 27, No. 4 scription, are sought for the treatment of various gene-related diseases. 18) As examples of such antigenes, it has been reported that oligopyrimidine nucleotides partially modified with ENA residues can form a triplex with dsDNA at physiological pH. 15) These oligonucleotides form triplexes similarly to those partially modified with 2Ј,4Ј-BNA/LNA residues, as determined by UV melting analyses, electromobility shift assays, CD spectral analyses and restriction enzyme inhibition assays.
Moreover, although no triplex is formed with fully modified 2Ј,4Ј-BNA/LNA, oligonucleotides fully modified with ENA, which are all in the C3Ј-endo conformation, have high triplex formation ability. 15) This conformation state may explain why the ENA units of these oligonucleotides have torsion angle d values that are marginally higher than 2Ј,4Ј-BNA/LNA by 11°/unit as described above. These results provide useful information for designing fully modified antigene oligonucleotides using modified nucleosides, which are all in the C3Ј-endo conformation.
APPLICATION OF ENA OLIGONUCLEOTIDES AS ANTISENSE MOLECULES
Some examples of applications using ENA oligonucleotides as antisense molecules have been reported. 17, 19, 20) ENA-DNA-ENA gapmer-designed oligonucleotides that can undergo RNase H-mediated degradation are used as AONs. When ENA-modified AONs against vascular endothelial growth factor (VEGF) mRNA were introduced into human cancer A549 cells in the presence of a cationic polymer, more than 90% inhibition of VEGF mRNA production was observed after RT-PCR analysis. 17) Mismatched ENA AONs did not show any inhibitory activity. These results indicate that ENA AONs act in a sequence-specific manner and could be used as effective antisense drugs.
AONs that specifically target the genes of rat organic anion transporting polypeptide (oatp) subtypes were selected by using antisense in vitro selection and a conventional gene alignment program. 19, 20) When several ENA residues were incorporated into AONs, the inhibitory activity of these oatp AONs was enhanced. Moreover, these ENA AONs did not lose their oatp-subtype selectivity.
By introducing oligonucleotides, a new technology associated with exon-skipping has been developed whereby RNA may be modified to acquire new properties, as shown in Fig.  3 . 21, 22) Splicing-related proteins, such as U1 and U2 snRNP, bind to pre-mRNA and play rule in the splicing of premRNA to mature mRNA. These proteins recognize splicing enhancer sequences (SES) to promote a splicing reaction. An AON binding to one of SES in the pre-mRNA could prevent the splicing reaction of the exon. Duchenme muscular dystrophy (DMD) is a rapid and progressive muscle-wasting disease, which is characterized by the absence of dystrophin in the muscle. On the other hand, Becker muscular dystrophy (BMD) is a less-severe form of the disease. Both DMD and BMD are allelic diseases that cause deletion mutations. Although the translational reading frame of the dystrophin gene in DMD is out-of-frame, that in BMD is in-frame. 21) Antisense PS ODN against a particular region of exon 19 of the dystrophin gene have been shown to induce exon-skipping of exon 19 derived from patients, who have an out-of-frame dystrophin gene and to promote the expression of internally deleted dystrophin by correcting the translational reading frame. 23) To make highly active molecules that induce exon skipping, oligonucleotides having the same sequence as the PS ODN but with some stretches of modified backbone, 2Ј-O-methyl RNA with several ENA residues at both the 5Ј and 3Ј ends, were designed.
24) The 2Ј-O-methyl RNA/ENA chimera induced exon-19 skipping in a dose-and time-dependent manner. The exon-19-skipping activity of the 2Ј-Omethyl RNA/ENA chimera was more than 40 times stronger than that of the corresponding conventional PS ODN.
CLOSING REMARKS
AONs are widely applied not only in vitro but also in vivo to elucidate the mechanisms of target genes related to diseases such as cancer, inflammation and diabetes. 2, 3, 6) In particular, nuclease-resistant oligonucleotides with ENA residues could have be used as antisense and antigene oligonucleotides because of their high binding affinity to mRNA and dsDNA, respectively, and their nuclease-resistance. As well, ENA oligonucleotides might be used as a tool in functional genomics.
NOTE
In Japan, ENA oligonucleotides having 2Ј-O,4Ј-C-ethylene nucleosides are commercially available from Sigma Genosys Japan (http://www.genosys.co.jp). ENA is a trademark of Sankyo Lifetech Co., Ltd. 
